iRhythm Holdings reported second-quarter 2026 sales of $224.17 million and a narrowed net loss of $0.381 million, while raising its full-year 2026 revenue guidance to $880 million to $890 million and announcing a proposed $45.00 million securities class action settlement related to Zio AT device disclosures. The upgraded outlook and litigation progress come alongside the planned VitalConnect acquisition, giving investors a clearer view of both growth potential and legal overhang in the ambulatory cardiac monitoring business. The company’s narrative now projects $1.2 billion in revenue and $97.8 million in earnings by 2029, implying a fair value of $178.93 per share, a 40% upside to the current price.
iRhythm Technologies IncRaises 2026 revenue guidance and proposes settlement, improving outlook and reducing legal overhang.
